indicated, in addition to standard therapy including beta-blockers, to reduce the risk of cardiovascular (CV) mortality and morbidity in stable patients with left ventricular dysfunction (LVEF = 40%) and clinical evidence of heart failure after recent myocardial infarction (MI).